The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. Keytruda (Merck) and Tecentriq (Roche / Genentech) have since been approved for previously untreated patients, and Keytruda saw a quick FDA approval in the non-muscle-invasive, BCG-unresponsive population as immune checkpoint inhibitors are becoming spread across different stages of disease. Biomarker-driven treatments are becoming increasingly attractive, as highlighted by Balversa’s FDA approval in April 2019. Furthermore, the entrance of Padcev in the third-line setting in the United States provides patients with an extra treatment option for metastatic disease. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.
- What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?
- How is bladder cancer currently treated, and what are the (dis)advantages of existing drugs? What is the expected market impact of recent approvals?
- Which of the emerging therapies seem most promising, and what sales/uptake could they secure in the bladder cancer market?
- What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the ten-year forecast period?
Geographies: United States, EU5, Japan.
Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands/generics and epidemiological subpopulations.
Emerging Therapies: Phase III/PR: 9 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Bladder Cancer - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Grace Mitchell, M.Res; Narendra Parihar
is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a B.Sc. in Biomedical Science from the University of Reading.
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.